Saito et al., 2003 - Google Patents

Assessment of fatty acid metabolism in taxan-induced myocardial damage with iodine-123 BMIPP SPECT: comparative study with myocardial perfusion, left ventricular …

Saito et al., 2003

View PDF
Document ID
125081907697709648
Author
Saito K
Takeda K
Imanaka-Yoshida K
Imai H
Sekine T
Kamikura Y
Publication year
Publication venue
Annals of nuclear medicine

External Links

Snippet

We investigated myocardial fatty acid metabolism in taxan-induced myocardial damage in patients with advanced lung cancer. Patients and Methods: Twenty-five patients with non- small-cell lung cancer were treated with taxan combined with carboplatin intravenously for …
Continue reading at jsnm.sakura.ne.jp (PDF) (other versions)

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form

Similar Documents

Publication Publication Date Title
US11071770B2 (en) Methods for detecting cardiac damage
Mitani et al. Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era
Maes et al. Histological alterations in chronically hypoperfused myocardium. Correlation with PET findings.
Avril et al. Monitoring response to treatment in patients utilizing PET
Cochet et al. Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer
Saito et al. Assessment of fatty acid metabolism in taxan-induced myocardial damage with iodine-123 BMIPP SPECT: comparative study with myocardial perfusion, left ventricular function, and histopathological findings
Ruggiero et al. Anthracycline cardiotoxicity in childhood
Wachters et al. Cardiotoxicity in advanced non-small cell lung cancer patients treated with platinum and non-platinum based combinations as first-line treatment
Kremer et al. Indium-111–Antimyosin Scintigraphy in the Early Detection of Heart Damage After Anthracycline Therapy in Children
Wakabayashi et al. Assessment of Doxorubicin Cardiac Toxicity Using Gated 99mTc-Hexakis-2-Methoxyisobutylisonitrile Myocardial Single Photon Emission Computed Tomography–Wall Thickening and Motion Abnormalities Can Be an Early Sign of Cardiac Involvement–
Goncalves et al. High-dose alkylating agents with autologous hematopoietic stem cell support and trastuzumab in ERBB2 overexpressing metastatic breast cancer: a feasibility study
Fujino et al. Recovery of BMIPP uptake and regional wall motion in insulin resistant patients following angioplasty for acute myocardial infarction
De Maria et al. Morphological bases for thallium-201 uptake in cardiac imaging and correlates with myocardial blood flow distribution
Li et al. Immune myocarditis induced by sintilimab therapy: A case report
Kucukosmanoglu et al. Correlation of [18F] FDG PET activity with expressions of Ki-67 in non-small-cell lung cancer
Gemma et al. Phase I/II study of paclitaxel+ carboplatin for refractory or recurrent non-small cell lung cancer
AU2014202390B2 (en) Methods for detecting cardiac damage
Dompieri et al. Nuclear Medicine Tools for Cardiac Damage Diagnosis in Oncology
堀優作 Preclinical evaluation using in vivo radiological imaging in mouse cancer models
Costedoat-Chalumeau et al. CNS involvement and treatment with interferon-are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients
Cowley et al. Functional diagnostic imaging in the assessment of myocardial viability
Teresińska et al. Assessment of myocardial perfusion and viability with stress Tc-99m-MIBI SPECT before surgical revascularisation. Correlation with postoperative perfusion improvement
Viale et al. Cardiovascular toxicity associated with cancer treatment [corrected][published erratum appears in CLIN J ONCOL NURS 2008 Oct; 12 (5): 705].
Catalin Loghin et al. Articles in PresS. Am J Physiol Heart Circ Physiol (September 1, 2006). doi: 10.1152/ajpheart. 00818.2006